Tadalafil Treatment in Patients With Cerebral Small Vessel Disease: The ETLAS-2 Randomized Clinical Trial
Authors:
- Joakim ÖlmestigJÖJoakim Ölmestig
- Kristian Nygaard MortensenKMKristian Nygaard Mortensen
- Marie Bjerregaard ThomasMTMarie Bjerregaard Thomas
- Birgitte FagerlundBFBirgitte Fagerlund
- Nadia NaveedNNNadia Naveed
- Mette Maria NordlingMNMette Maria Nordling
- Marie Katrine Klose NielsenMNMarie Katrine Klose Nielsen
- Brian Schou RasmussenBRBrian Schou Rasmussen
- Hanne ChristensenHCHanne Christensen
- Helle Klingenberg IversenHIHelle Klingenberg Iversen
- Mai Bang PoulsenMPMai Bang Poulsen
- Hartwig Roman SiebnerHSHartwig Roman Siebner
Open Access
- 1 October 2025
- journal article
- research article
- Published by Wolters Kluwer Health in Stroke
- Vol. 56 (10) , 2846-2857
Abstract
BACKGROUND: White matter hyperintensities and reduced cerebral blood flow are hallmarks of cerebral small vessel disease (CSVD). We tested the feasibility of daily treatment with the vasoactive drug tadalafil in patients with CSVD and its effects on cognition and imaging markers of CSVD. METHODS: The ETLAS-2 trial (Effect of Tadalafil in Lacunar Stroke) was a randomized, placebo-controlled, double-blind, parallel phase II trial testing 3 months of daily tadalafil 20 mg versus placebo in patients with CSVD and previous stroke or transient ischemic attack. Participants were included from the Capital Region of Denmark from 2022 to 2024. Outcomes were assessed at baseline and after 3 months. A binary logistic regression model with the treatment group as a covariate was used to calculate the primary outcome of feasibility (≥90% study drug compliance). Secondary outcomes included the Montreal Cognitive Assessment, magnetic resonance imaging markers of CSVD (Standards for Reporting Vascular Changes on Neuroimaging criteria), blood pressure, and adverse events. RESULTS: We included 76 participants (20 female, mean age, 68.0±8.9 years). Seventy-one initiated treatment, and 26 of 38 participants with tadalafil were ≥90% compliant versus 31 of 33 with placebo (odds ratio, 0.13 [95% CI, 0.03–0.69]; P =0.030). There was a female preponderance in tadalafil dropouts, with 46% of females stopping treatment, compared with only 16% of males. Adverse events occurred in 76% of participants with tadalafil versus 36% with placebo (odds ratio, 5.49 [95% CI, 1.81–18.07]; P =0.001). A trend toward lower white matter hyperintensity volume at follow-up was observed in the tadalafil group in the unadjusted per-protocol analysis (relative change, 0.939 [95% CI, 0.881–1.001]; P =0.054). No differences were observed in cognition, mental well-being, or blood pressure. CONCLUSIONS: In participants with CSVD, adherence to tadalafil was significantly lower than to placebo and did not meet the prespecified compliance threshold. We observed a nonsignificant reduction in white matter hyperintensity volume after tadalafil, which warrants larger and prolonged studies with reduced tadalafil doses to explore potential benefits in CSVD. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05173896.Keywords
This publication has 30 references indexed in Scilit:
- Isosorbide Mononitrate and Cilostazol Treatment in Patients With Symptomatic Cerebral Small Vessel DiseaseJAMA Neurology, 2023
- Neuroimaging standards for research into small vessel disease—advances since 2013The Lancet Neurology, 2023
- An open-source tool for longitudinal whole-brain and white matter lesion segmentationNeuroImage: Clinical, 2023
- The PASTIS trial: Testing tadalafil for possible use in vascular cognitive impairmentAlzheimer's & Dementia, 2022
- Small vessel disease: mechanisms and clinical implicationsThe Lancet Neurology, 2019
- Tolerability, safety and intermediary pharmacological effects of cilostazol and isosorbide mononitrate, alone and combined, in patients with lacunar ischaemic stroke: The LACunar Intervention-1 (LACI-1) trial, a randomised clinical trialeClinicalMedicine, 2019
- Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegenerationThe Lancet Neurology, 2013
- Silent Ischemic Lesion Recurrence on Magnetic Resonance Imaging Predicts Subsequent Clinical Vascular EventsArchives of Neurology, 2006
- Side-effect profile of sildenafil citrate (Viagra) in clinical practiceUrology, 2000
- A short form of the Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE): development and cross-validationPsychological Medicine, 1994